Physician profile
Nirupama P Patel
NPI 1831156975
$1,183.98
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $112 · 2021: $193 · 2022: $196 · 2023: $272 · 2024: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $512.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $390.22 | 2021-2024 | Qelbree, Qelbree |
| Glaxosmithkline, LLC. | $208.48 | 2019-2024 | Bexsero |
| Ironshore Pharmaceuticals INC. | $170.04 | 2020-2024 | Jornay Pm |
| Alexion Pharmaceuticals, INC. | $110.98 | 2019-2020 | |
| Corium, LLC | $106.23 | 2021-2023 | Azstarys |
| Merck Sharp & Dohme LLC | $39.04 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $38.06 | 2019 | |
| Pfizer INC. | $30.73 | 2020-2022 | |
| Genentech USA, INC. | $22.33 | 2020 | |
| Tris Pharma INC | $16.33 | 2024 | Dyanavel Xr |
| Sanofi Pasteur INC. | $14.85 | 2021 | |
| Adlon Therapeutics L.P. | $12.44 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.41 | 2020 | |
| Shire North American Group INC | $11.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirupama Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.